Gastroesophageal Reflux  >>  lucitanib (E 3810)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lucitanib (E 3810) / Clovis, Servier
NCT00165646: A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease

Completed
3
288
Japan
E3810, Placebo
Eisai Co., Ltd.
Non-erosive Gastroesophageal Reflux Disease
10/05
10/05
NCT00165672: A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease

Completed
3
26
Japan
RABEPRAZOLE SODIUM
Eisai Inc., Eisai Limited
Non-erosive Gastroesophageal Reflux Disease
10/05
10/05
NCT02135107: A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients

Completed
3
517
Japan
Rabeprazole, E3810
Eisai Co., Ltd.
Gastroesophageal Reflux Disease
05/16
06/16
NCT00770913: Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis

Completed
2/3
337
Japan
E3810, Aciphex
Eisai Co., Ltd.
Refractory Reflux Esophagitis
11/09
03/10

Download Options